Stéphane Palfi email@example.com
A French and English team (AP-HP, Inserm, UPEC, CEA/Mircen, Oxford Biomedica, Cambridge University) has conducted a clinical phase 1/2 gene therapy study among patients suffering from an evolved form of Parkinson’s disease. Fifteen patients were able to benefit from this new treatment, which involves injecting a vector expressing the genes of three enzymes that are essential for the biosynthesis of dopamine, which is lacking in Parkinson’s disease. Thanks to this therapy certain cells in the brain begin to produce and secrete dopamine again. In all the patients, the motor symptoms of the disease were improved for up to 12 months after administration of the treatment. After a period of four years, this study is at this stage demonstrating innocuousness and tolerance of the lentiviral vector used for the first time in human beings. This study was coordinated by Prof. Stéphane Palfi, head of neurosurgery at Henri-Mondor Hospital (AP-HP) within the framework of the neurolocomotor research cluster directed by Prof. Césaro.
It is the subject of a publication in The Lancet
Parkinson’s: a common neurodegenerative disease
With about 120,000 patients in France, Parkinson’s disease is the most common neurodegenerative disorder after Alzheimer’s disease. It essentially manifests itself through motor symptoms that steadily grow and become more severe such as trembling, rigidity of the limbs and diminished movement of the body. This pathology is due to the degeneration of neurons that produce dopamine, a neurotransmitter that participates in motor control .
Currently, the treatment of people affected by this disease consists of taking medication that mimics the action of the dopamine missing in the brains of these patients. While this treatment makes it possible to improve motor activity considerably during the first stages of the disease, severe undesirable effects appear at the end of this time such as fluctuations in the effect of the treatment and abnormal involuntary movements, called dyskinaesia.
Developing a new treatment that permits the physiological restoral of missing dopamine
For several years, experts on Parkinson’s disease, researchers and doctors, have held the hypothesis that the intermittent intake of medication during the day alters the functioning of the brain by stimulating neurons in an excessively irregular manner. This phenomenon would constitute the origin of the complications connected with dopaminergic treatment.
The currently most pressing issues in the treatment of Parkinson’s disease thus concern the development of a technology that would make it possible to induce:
This is why researchers today are turning to gene therapy, which consists of causing a therapeutic gene to be expressed directly by brain cells.
Gene therapy consists of introducing therapeutic genes in vivo so that they express directly in the targeted cells.
It rests on the use of viral vectors such as lentiviruses, adenoviruses and AAVs (adeno-associated viruses), which have the ability to introduce their genetic material into the nucleus of host cells.
Some requirements must be absolutely satisfied for a wild virus to be able to be transformed into a vector with the ability to ensure the transfer of genes of therapeutic interest in complete security. These viral envelopes are stripped of their properties for multiplication and rendered non-pathogenic.
Increasing the synthesis of dopamine through gene therapy
In the majority of cases, Parkinson’s disease does not have a genetic origin. However, the biochemical modifications responsible for the symptoms can be corrected by using a gene therapy strategy of the ‘replacement or restoral of function’ type in order to increase the synthesis of dopamine (by expressing genes involved in the biosynthesis of dopamine) and restore the function of dopaminergic cells partially.
It is this approach that was adopted in the phase I/II biomedical study coordinated by Prof. Stéphane Palfi (Henri-Mondor Hospital, AP-HP), the results of which have just been published.
Fifteen patients were operated on by Prof. Palfi, coordinating investigator, in two centres of excellence in neurosurgery – Henri Mondor Hospital (AP-HP) in France and Addenbrookes Hospital in Cambridge, UK.
For the first time in human beings, the team used a lentiviral vector which expresses the genes of three enzymes – AADC (decarboxylase of aromatic amino acids), TH (tyrosine hydroxylase) and CH1 (GTP-cyclohydrolase 1) – essential in the biosynthesis of dopamine. The product was administered in the area of the brain called the striatum during a heavy surgical operation.
Once in the right place, the genes contained in the lentivirus can express themselves and reprogramme cells, which begin to produce and secrete dopamine in the extracellular environment.
Three increasing dosage levels (1×, 2× and 5×) were tested.
‘This biomedical gene therapy study shows innocuousness over the long-term transfer of genes by the lentiviral vector when it is injected directly into the brain of patients suffering from Parkinson’s disease’, explains Prof. Stéphane Palfi. ‘The clinical analysis suggests that the vector used enables a reduction in motor symptoms depending on the vector dose administered, with the strongest dose being the most effective .
The objective of future clinical developments of the vector will be to confirm an improved viral construction that would make it possible to induce an increased release of dopamine (phase 2a). This phase will be followed by a study of the therapeutic effect of ProSavin® by comparing a group of patients receiving the treatment and another group not receiving the treatment (phase 2b). This study, which is pioneering the use in gene therapy of a lentivirus injected in situ, will definitely open up new therapeutic perspectives for diseases of the nervous system.’
Architecture of phase I/II clinical trial
15 patients treated
1 lentiviral vector used for the first time in humans
3 dosage levels tested
Research initiated in 2009
This clinical trial follows on from a preclinical study published in 2009, which showed for the first time the effectiveness and innocuousness of the medication in an animal model. Carried out within the framework of the MIRCen translational platform of the CEA, it has opened the door to the clinical study of ProSavin®.
Des chercheurs de Généthon, le laboratoire de l’AFM-Téléthon, et de l'Inserm, en collaboration avec la biotech américaine Selecta Biosciences, démontrent la possibilité de ré-administrer une thérapie génique par vecteur AAV (virus adéno-associé), sans réponse immunitaire, grâce à des nanoparticules de rapamycine, un ...
Stéphane Palfi firstname.lastname@example.org
Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial The Lancet, january 2014